SUMMARY In two groups of gallstone patients ideally suited for medical treatment, the effect of six to 18 months' therapy was compared retrospectively in 52 given chenodeoxycholic acid (CDCA) and 46 given ursodeoxycholic acid (UDCA). The minimum dose (mg kg-1day-1) 18 months' treatment with CDCA and UDCA in diminishing the saturation of bile with cholesterol and in dissolving gallstones. We also compared the frequency and severity of symptons (such as biliary colic and non-specific dyspepsia) and the incidence of side-effects, before and during treatment. This paper reports our findings.
FASTING SERUM LIPIDS AND LIVER FUNCTION TESTS
Fasting serum cholesterol and triglyceride levels together with serum gamma glutamyl transpeptidase (yGT), bilirubin, aspartate amino-transferase (AAT), alkaline phosphatase (AP), total protein and albumin were measured in the hospital clinical chemistry laboratory. Fig. 1 . From these data it seems that the relationship between these variables is curvilinear rather than linear.
Mean dose producing gallstone dissolution in 'responders' The UDCA dose in the 23 'responders' who showed radiological evidence of partial or complete gallstone dissolution after six months' therapy ( Twelve patients in the UDCA group were treated for 18 months or more. In eight of these, the gallstones showed progressive, but as yet incomplete, dissolution, while two showed complete dissolution of gallstones at radiography 18 months after treatment. Another patient, whose gallstones remained unchanged despite ursotherapy, was found on follow-up radiography to have radioopaque calcified rims to her gallstones-Because the quality of the initial radiography in this patient was indifferent, it was not possible to say whether the calcification was present before treatment or whether it was acquired during therapy. In the twelfth patient, because the radiographs remained unchanged in spite of 18 months' treatment with an adequate dose of UDCA (10.8 mg kg-'day-'), unsaturated bile (an on-treatment saturation index of 0.60) and UDCA-enriched bile (UDCA conjugates accounting for 42% of the biliary bile acids), radiolucent non-cholesterol gallstones were suspected. This was subsequently confirmed: at cholecystectomy small pigment-rich stones were removed which, on analysis, were found to contain no measurable amounts of cholesterol.
SYMPTOMS AND SIDE-EFFECTS
The incidence of non-specific dyspeptic symptoms before and during bile acid treatment and the frequency of episodes of biliary colic, comparing the incidence in the years before treatment with that seen during six to 18 months' therapy, are shown in 'pie-graph' form in Fig. 2 .
Non-specific dyspepsia (Fig. 2, left panel) Before treatment, 67% of patients complained of non-specific abdominal symptoms but during UDCA was more effective than CDCA in desaturating bile and in promoting more rapid dissolution of gallstones. The latter approach has already been adopted for studies of bile lipid composition. In a crossover study on 10 patients, Stiehl et al. 20 compared the effects of approximately 15 (range 12.7-17.9) mg of UDCA kg-'day-' and of the same doses of CDCA, on fasting biliary cholesterol saturation. They showed that with CDCA, the mean on-treatment saturation index was 0.8 ±01, while with UDCA it was 0*6±01. By implication, therefore, one might expect more rapid gallstone dissolution with UDCA. As yet, there have been few studies in man where gallstone dissolution rates have been correlated with the degree of desaturation of bile during treatment, but the results of studies in the Rhesus monkey suggest that the speed of gallstone dissolution is indeed inversely related to biliary cholesterol saturation. 21 The present results show that, in some patients, desaturation of fasting duodenal bile can occur with doses as small as 4.0 mg/kg for CDCA and 2.1 mg/kg for UDCA. These results with CDCA lend indirect support to Danzinger's findings22 that gallstone dissolution occurs occasionally with small CDCA doses. However, the recommended bile acid dose should not be the minimum dose which desaturates bile but the one which does so consistently. From the results of the present and other studies,11 23 we would still recommend a dose of 7-10 mg UDCA kg-'day-' and 13-15 mg CDCA kg-'day-'. there was no additional benefit to be gained by increasing the dose of UDCA.
Clearly, many patients will develop unsaturated bile with less UDCA than the recommended dose. Indeed, it has even been suggested that it is a disadvantage to have UDCA-rich bile for gallstone dissolution because in UDCA.rich ' The efficacy of six months' treatment with the two bile acids was high, although at both six and 12 months, the 81 and 89% efficacy figures for CDCA were higher than the corresponding figures for UDCA (66 and 76% respectively). This nonsignificant difference may be due to the fact that some of the 16 UDCA-treated patients who took part in the dose-response studies had suboptimal UDCA doses for the first six to 12 weeks of their study.
The reduction in dyspeptic symptoms and in the frequency and severity of biliary colic seen during treatment with both bile acids extends previous uncontrolled observations from our own unit 6 and elsewhere. 38 The strong possibility that this is a placebo effect has been made less likely by the results of two short-term, double-blind trials comparing UDCA and placebo. 39 40 The mechanism for these apparent benefits is unknown and is currently under study in our unit. 45 Given their structural similarities, it might at first sight seem surprising that treatment with CDCA should result in hypertransaminasaemia while treatment with its 7,B epimer, UDCA, does not. However, the apparently minor positional change of the 7 hydroxyl group results in quite marked differences in the spatial relationship between 3 and 7 hydroxyl groups on the molecule and this could well alter the surface-active properties of the two bile acids. Indeed, this explanation has been advanced to explain the differences in the incidence of diarrhoea seen with CDCA and UDCA. 4' When comparing the pros and cons of CDCA and UDCA, two other aspects merit discussion -the development of calcified rims to gallstones during therapy and the possibility that the cost and sideeffects of CDCA treatment might be reduced by low-dose, bedtime administration of the bile acid. In the present study, one patient seemed to have developed calcification at the periphery of his gallstone during treatment which may well render further dissolution therapy ineffective. To date, there is little published information about this phenomenon, but several groups have reported similar findings.42 43 Whether this occurs more often during bile acid therapy than would happen spontaneously, whether it occurs only with UDCA and not with CDCA and whether, as a predisposing factor, calcium solubility is impaired in UDCA-rich bile, remains to be proven. Similarly, Northfield's group have shown that low-dose, bedtime administration of CDCA desaturates fasting duodenal bile and produces partial gallstone dissolution more rapidly than divided CDCA doses.44 If more rapid or effective complete gallstone dissolution is proved by this group and confirmed by others and if this benefit is specific to CDCA and not to UDCA, then the apparent advantages of UDCA might well be negated. 
